Related Experiment Video

Updated: May 17, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Urological cancer: Enzalutamide in metastatic CRPC-old dog, new tricks

Che-Kai Tsao, William K Oh

    Nature Reviews. Clinical Oncology
    |October 10, 2012
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
    06:32

    Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

    Published on: November 4, 2022

    Related Experiment Videos

    Last Updated: May 17, 2026

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
    07:25

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

    Published on: March 6, 2018

    Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
    06:32

    Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

    Published on: November 4, 2022

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Urinary Tract Calculi III: Medical Management01:30

    Urinary Tract Calculi III: Medical Management

    The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...

    Articles linked to this work by shared authors, journal, and citation graph.

    Efficacy of PARP inhibitor and immune checkpoint inhibitor combination therapy in PD-L1-negative cancers: a systematic review and meta-analysis.

    Immunotherapy·2026

    Long-Term Survival Outcomes of Immune Checkpoint Inhibitor-based Combination Therapies in Favorable-Risk Metastatic Renal Cell Carcinoma: An Updated Pairwise and Network Meta-Analysis.

    Clinical genitourinary cancer·2026

    The Role of Gut Microbiome in Prostate Cancer: Current Evidence and Emerging Opportunities.

    Cancers·2026

    Navigating the winding road toward precision prostate cancer care.

    Gene·2025

    Can PARP Inhibitors Benefit Patients with Homologous Recombination Repair-Proficient Castration-Resistant Prostate Cancer? A Meta-analysis.

    Targeted oncology·2025

    Artificial intelligence in oncology: promise, peril, and the future of patient-physician interaction.

    Frontiers in digital health·2025

    Optimizing the delivery of radiotherapy with artificial intelligence.

    Nature reviews. Clinical oncology·2026

    Understanding and targeting the tumour matrisome.

    Nature reviews. Clinical oncology·2026

    Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology.

    Nature reviews. Clinical oncology·2026

    Exploring the landscape of targetable alterations in patients with glioblastoma.

    Nature reviews. Clinical oncology·2026

    AI-based augmentation of oncology clinical trials.

    Nature reviews. Clinical oncology·2026

    Clinical toxicity of ADCs and ICI-ADC combinations: mechanisms, patterns and management.

    Nature reviews. Clinical oncology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us